尤因唐通过解决元炎症减轻肥胖引起的喘
1Department of Basic Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
Pharmaceuticals (Basel, Switzerland)
|July 27, 2024
概括
尤因通过减少小鼠的炎症和代谢功能障碍,有效治疗肥胖引起的喘 (OIA). 这种草药可能为OIA患者提供一种新的治疗方法.
科学领域:
- 东亚传统医学 东亚传统医学
- 免疫学 免疫学 免疫学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 肥胖与肥胖诱导的喘 (OIA) 有关,可能由湿度介导.
- 众所周知,尤因唐可以降低肥胖和高血压.
研究的目的:
- 在小鼠模型中研究euiin-tang在减轻高脂肪饮食 (HFD) 诱导的OIA中的有效性.
- 探索euiin-tang对OIA采取行动的潜在机制.
主要方法:
- 给C57BL/6小鼠了15周的HFD,以诱导OIA.
- 在HFD养的最后五周内,Euiin-tang是口服的.
- 评估的体重,肝脏重量,呼吸道过敏,免疫细胞透,组织学变化,细胞因子表达,巨分化和阿迪波金水平.
主要成果:
- 尤因抑制了HFD诱导的体重增加,肝脏体重增加,呼吸道过敏和免疫细胞透.
- 用euiin-tang治疗减少了肺部和脂肪组织炎症,粘膜炎症,过分分泌和纤维化.
- 尤因-调节了巨细胞极化从M1变为M2表型,并逆转了HFD诱导的阿迪波内克和莱普水平的变化.
结论:
- 尤因显示出作为治疗肥胖引起的喘的治疗剂的潜力.
- 这种草药通过抑制HFD诱导的元炎症来缓解OIA,其特点是炎症性细胞因子表达减少和改善代谢概况.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
264
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
264
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma: Pathogenesis and Management
379
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
379
Drugs Used in Lower Respiratory Disorders: Overview
386
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
386
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K


